Main Location: 1180 N Indian Canyon Drive, E319, Palm Springs, CA 92262-4809
Second Location: 41-990 Cook Street, Building G. Ste 601, Palm Desert, CA 92211
 
 
 
 
Desert Heart Physicians
 
PALM SPRINGS 760-325-1203
PALM DESERT 760-360-4446
 
 
 
 
 
 

JON R. SHERMAN, M.D., F.A.C.P., F.A.C.C., F.S.C.A.I.

EDUCATION:

 
Postgraduate:
 
Certificate in Leadership for Healthcare Transformation 2014
The Paul Merage School of Business
University of California, Irvine
 
 
Fellowship:
 
Specialty: Interventional Cardiology 1995-1996
Sequoia Hospital
170 Alameda De Las Pulgas
Redwood City, CA 94062
 
 
Fellowship:
 
Specialty: Cardiovascular Diseases 1992-1995
Baylor University Medical Center
3500 Gaston Avenue
Dallas, TX 75248
 
 
Residency:
 
Specialty: Internal Medicine 1990-1992
University of Colorado Health Sciences Center
4200 East Ninth Avenue
Denver, CO 80262
 
 
Internship:
 
Specialty: Internal Medicine 1990-1992
University of Colorado Health Sciences Center
4200 East Ninth Avenue
Denver, CO 80262
 
 
Medical School:
 
Doctor of Medicine 1989
University of Texas Health Science Center
7000 Fannin, Suite 2250
Houston, TX 77030
 
 

Jon R. Sherman, M.D., Curriculum Vitae

 
Undergraduate:
 
Bachelor of Arts with Honors 1984
Plan II Liberal Arts Honors Program
University of Texas at Austin, Main Bldg., Room 1
Austin, TX 78712
 

CERTIFICATION:

National Board of Physicians and Surgeons, recertified 2017
Internal Medicine, Cardiovascular Diseases and Interventional Cardiology
ACLS/BLS, recertified 2016
Diplomate ABIM, Subspecialty Board of Interventional Cardiology, recertified 2011
Diplomate ABIM, Subspecialty Board of Cardiovascular Diseases, recertified 2009
Diplomate ABIM, American Board of Internal Medicine
Level II Certification, Society of Cardiovascular Computed Tomography
Federation of State Medical Boards

HOSPITAL AFFILIATIONS:

Longs Peak Hospital, 1750 E Ken Pratt Parkway, Longmont, CO 80501 08/17-present
Medical Center of the Rockies, 2500 Rocky Mountain Avenue, Loveland, CO 80538 04/17-present
St. Jude Medical Center, 101 East Valencia Mesa Drive, Fullerton, California 92835 04/98-03/17
Placentia-Linda Hospital, 1301 Rose Drive, Placentia, California 92870 11/09-03/17
UCI Medical Center, 101 The City Drive South, Orange, CA 92868-3298 02/04-01/17
Valley View Hospital, 1906 Blake Avenue, Glenwood Springs, CO 81601 06/14-12115 (Locurns)
Longmont United Hospital, 1950 Mountain View Avenue, Denver, CO 80501 10/15-12116 (Locums)
Denver Health, 777 Bannock St., Denver, CO 80204 06/16-12/16 (Locurns)

EMPLOYMENT HISTORY:

UCHealth 04/17
Harbor Heart 07/07-04117
St. Jude Heritage Medical Group 04/98-07/07
Phoenix Heart 12/97-04/98
HeartPlace 09/96-12/97

ACADEMIC APPOINTMENT:

University of California, Irvine College of Medicine
Assistant Clinical Professor, Cardiology, 2004-2017
Relevance Reviewer, American Board of Internal Medicine
Interventional Cardiology Board Exam 2005-2015

HONORS/AWARDS:

Orange County Medical Association Physicians of Excellence Awards

PROFESSIONAL MEMBERSHIPS:

Society of Cardiovascular Computed Tomography (SCCT), Founding Member 2005
Heart Failure Society of America (HFS), Member 2003
Society for Cardiovascular Angiography and Interventions (SCAI), Fellow 2002
American College of Chest Physicians (ACCP), Fellow 2002
American College of Cardiology (ACC), Fellow 2000
American College ofPhysicians (ACP), Fellow 1999
 
Boulder County Medical Society 2017-present
Colorado Medical Association 2017-present
OCMA Board of Directors, District 1 Representative 2000-2004
OCMA (Orange County) 1998-2016
California Medical Association 1998-2016
MCMS (Maricopa County) 1998
DCMS (Dallas County) 1992-1997
HCMS (Harris County) 1985-1989
Medical Student Committee 1986-1989
Chairman, Task Force on Legislation 1988-1989
Medical Student Leader, TMA House of Delegates 1988-1989
Chapter Delegate, TMA House of Delegates 1987-198
Council on Medical Education 1987-1989
Council on Public Health 1986-1987
Texas Medical Association 1985-1989
Chapter President, University of Texas Medical School at Houston 1986-1987
American Medical Association 1985-present

PROFESSIONAL INTERESTS:

Interventional Cardiology & Diagnostic Cardiac Catheterization
  • Femoral and Trans-Radial Artery Coronary Angiography and Interventions
  • Primary PCI for STEMI
  • IVUS, FFR, IFR
  • Orbital, Rotational and Directional Atherectomy
  • SVG Intervention with distal protection
  • Hemodynamic support
  • Vascular Closure devices
  • Emerging Interventional Techniques
Cardiac Rehabilitation and Wellness
Nuclear Cardiology
Transthoracic, Transesophageal and 3-D Echocardiography, CIMT
Stress Echocardiography and Exercise Treadmill Testing
Congestive Heart Failure
Cardiac Rhythm Management: Pacemaker/ICD/ILR Implantation and Follow-up
Electronic Health Records, Medical Informatics

ADMINISTRATION:

Longs Peak Hospital Pharmacy & Therapeutics Committee 2017
Harbor Heart, Founder and President 2007-2017
St. Jude Medical Center, Medical Director, Intensive (Omish) Cardiac Rehab 2015-2017
St. Jude Medical Center, Medical Director, Outpatient Cardiac Rehabilitation 2013-2017
St. Jude Medical Center Physician Informatics Advisory Committee 2013-2016
St. Jude Medical Center Physician Wellness Committee 2009
St. Jude Medical Center Medical Staff Quality Review Committee, Vice-Chair 2008
St. Jude Medical Center Cardiothoracic Department, Chairman 2006, 2007
St. Jude Medical Center Executive Medical Committee 2006-2007
St. Jude Medical Center Quality Committee 2006-2007
St. Jude Medical Center Credentials Committee 2006-2007
St. Jude Medical Center Cardiothoracic Executive Committee (CTEC), 2006-2007
St. Jude Medical Center Physician Advisory Council 2005-2007
St. Jude Medical Center Pharmacy and Therapeutics Committee 2005-2007
St. Jude Medical Center Judicial Review Committee, Chairman 2005
St. Jude Medical Center Leadership Council 2005-2008
St. Jude Medical Center Cardiology Department Quality Review Committee (QRC) 2001-2017
St. Jude Medical Center Critical Care Committee 1999-2001
St. Jude Medical Center Cardiology Department QM Committee 1998-2008
St. Jude Medical Center Cardiac Cath Lab Planning Committee 1998-2008
St. Jude Medical Center Institutional Review Board 1999
St. Joseph Heritage Healthcare North Orange County Division
Finance Committee Board of Directors 2002-2007
St. Jude Heritage Medical Group Board of Directors 2004-2007
1st Vice President 2005-2007
St. Jude Heritage Medical Group Executive Committee 1998-2005

ADVISORY BOARD(S):

Leonhardt Launchpads by Cal-X Stars Business Accelerator, Inc & Second Heart Assist, Inc
520 Broadway, Suite 200, Santa Monica, CA 90401

BIBLIOGRAPHY:Publications

1. Sherman, J.R., and Weinberg, R.B. Serum Apolipoprotein A-IV and Lipoprotein Cholesterol inPatients Undergoing Total Parenteral Nutrition. Gastroenterology, 95:394-401, 1988.
2. Sherman, J.R. and Anwar, A. et al. Distal Vessel Pullback Angiography and Pressure GradientMeasurement: An Innovative Diagnostic Approach to the No-reflow Phenomenon. Catheterizationand Cardiovascular Diagnosis, 39:1-6, 1996.
3. Del Campo, C, and Sherman, J. Tricuspid Valve Replacement: Results Comparing Mechanicaland Biological Prostheses. Ann Thoracic Surg 69:1295, 2000.
4. Tovar, Eduardo A., Sherman, Jon R., et al. Aortoscopy: A Less Invasive Intraoperative Method toAssess the Aortic Valve. Ann Thoracic Surg 73:284-286, 2002.
5. Lawrence S. Rosenthal, Ph.D., M.D., Stephen W. Mester, M.D., Peter Rakovec, M.D. J. BenezetPenaranda, M.D., Jon R. Sherman, M.D., Todd J. Shelton, M.S., Cathy Zeng, M.S., and PaulWang, M.D. for the CAPTURE Trial Investigators. Factors Influencing Pacemaker GeneratorLongevity: Results from the Complete Automatic Pacing Threshold Utilization Recorded in theCAPTURE Trial. PACE 33:1020-1030, 2010.
Abstracts:

1. Sherman, J.R., and Weinberg, R.B. Serum Apolipoprotein A-IV and Lipoprotein Cholesterol inPatients Undergoing Total Parenteral Nutrition. Gastroenterology, 92; 5(2): 1805, May 1987.
2. Heffner, K.D., and Sherman, J.R. et at. Predicting Peak Exercise Heart Rate From Age In CardiacPatients: Influence of Medications and Gender. Medicine and Science in Sports and Exercise, 26Suppl; 5. S184, May 1994.
3. Lawrence S. Rosenthal, Ph.D., M.D., Stephen W. Mester, M.D., J. Benezet Penaranda, M.D.,Jon R. Sherman, M.D., Raymond Gendreau, M.D., Yves R. Vandekerckhove, M.D.,Peter Rakovec, M.D., Jon Seltzer, M.S., Benjamin Rhodes, M.S., Michael Hull, M.S. Effect of Post-Mode Switch Overdrive Pacing on Atrial Tachyarrhythmia Average Daily Burden in LargeRandomized Trial. Heart Rhythm Society, May 2009.

CLINICAL TRIALS:

A Randomized, Double-Blind, Placebo-Controlled Study to compare the effects ofNabumetone 2g, Celecoxib 400mg and Ibuprofen 24 mg per day on Blood PressureControl in patients with hypertension stabilized on Antihypertension Therapy.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-findingStudy of Lercanidipine Hydrochloride in Patients with Essential Hypertension.

An Open-label Evaluation of the effectiveness of Micardis (Telmisartan) on Blood Pressure Controland Quality of Life in Patients with Essential Hypertension.

A phase IIIb, randomized, open-label trial with 3 parallel groups: full dose TNK-tPAtogether with heparin sodium; full dose TNK-tPA together with Enoxaparin; half doseTNK-tPA together with Abciximab and heparin sodium in patients with acute myocardial infarction.

A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCL vs.Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) DiabetesMellitus and Mild Cardiac Disease (NYHA 1).

A Randomized, Double-Blind, Placebo-Controlled Trial of Two Intravenous DosingRegimens of h5Gl.l-scFv in Patients with Acute Myocardial Infarction UndergoingThrombolytic Reperfusion Therapy.
A Randomized, Double-Blind, Placebo-Controlled Trial of Two Intravenous DosingRegimens ofh5G l.l-scFv in Patients with Acute Myocardial Infarction UndergoingPercutaneous Transluminal Coronary Angioplasty Reperfusion Therapy.

An Open-Label, Long-Term, Safety Study ofRanolazine SR for Chronic Stable AnginaPectoris at Doses of 500 mg, 750 mg and 1000 mg Twice a Day Administered inCombination with Background Anti-Anginal Therapy (CVT-3034).

A Double-Blind, Randomized, Stratified, Placebo-Controlled, Parallel Study ofRanolazine SR at Doses of750 mg Twice a Day and 1000 mg Twice a Day inCombination with Other Anti-Anginal Medications in Patients with Chronic StableAngina Pectoris.
A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of WeeklyAzithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposureto C. Pneumoniae.

A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the ClinicalEfficacy and Tolerability of Early Treatment with Simvastatin 40 mg Daily for 30 Days,Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary

Syndrome Patients Who Have Been Randomized to Receive Enoxaparin orUnfractionated Heparin in Conjunction with Aspirin, and in Optimally-Treated STElevation Acute Coronary Syndrome Patients.

A Multi-center, Randomized, Double-Blind, Placebo-controlled Study of the Effects on Blood Pressure ofTreatment with Nebivolol or Hydrochlorothiazide Alone and in Combination in Subjects with Mild toModerate Systemic Hypertension.

A Multicenter, Double-Blind, Randomized, Parallel, 28-week Study to Evaluate the Efficacy and Safetyof Simvastatin 80mg/day versus Atorvastatin 80mg/day in patients with Hypercholesterolemia (CHESScomparative HDL Efficacy and Safety Study).

Omapatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE)A Multicenter, Randomized, Double-Blind, Placebo-controlled, dose-ranging study of the long term (12weeks) Hemodynamic Effects, Safety, and Tolerability of study medication, a selective Endothelin-AReceptor Antagonist, in the Treatment of Heart Failure.

Study of the Costs Associated with the Use of the ACS Multi-link TristarrM Coronary Stent SystemCompared to Costs Associated with the Use of Other Stent Systems.

Effects of Oral N0-1886 on Lipoproteins in Subjects with Type II Diabetes Mellitus Who areReceiving Statin Therapy.

A Multicenter, randomized, controlled study in which patients are assigned in 1:1Proportions to use ofTRAPTM VFS device or control group without use of system.Determine the effectiveness of the TRAP VFS in providing distal embolizationProtection in coronary SVG intervention with PTCA and/or stenting.

Silent Atrial Fibrillation Detection with Stored EGMs (SAFE) Study. A Guidant U.S. MulticenterClinical Field Following Study. "Incidence of Asymptomatic Atrial Fibrillation in Bradycardia Patientswith Sick Sinus Syndrome."

A Phase III Randomized, Parallel, Double-Blind, Multicenter, Placebo-controlled Study of the Effect ofPexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary ArteryBypass Graft (CABG) Surgery with Cardiopulmonary Bypass.

Synergistic Effects of Risk Factors of Sudden Cardiac Death (SERF) Study. A Guidant MulticenterClinical Application Research Field Following Study.
Value of Electronically Recorded and Interrogated Follow-up via lPG Exported Data (VERIFIED). AMedtronic Pacemaker Registry.

Reported Atrial Fibrillation and Inappropriate Mode Switch in Sick Sinus Syndrome Patients (RARE)study. St. Jude Medical.

Clinical Observations on Usage, Learning and Trends (CONSULT) Kappa Pacemaker Program.Medtronic.

Limiting Chronotropic Incompetence for Pacemaker Recipients (LIFE) Study. Guidant.Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias (AWARE). St. JudeMedical.

Complete Automatic Pacing Threshold Utilization Recorded by EnPulse (CAPTURE) Clinical Study:A One-to-one Randomized, Multicenter, Prospective Study in Which Patients Receiving New EnPulsePacemaker Implants will be Randomized to Routine Manual Follow-up and Follow-up Using theAutomatic Features. Medtronic.

Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy andSafety of Two Blinded Doses of Dabigatran Etixilate with Open Label Warfarin for the Prevention ofStroke and Systemic Embolism in Patients with Non-Valvular AtrialFibrillation: Prospective, Multi-Centre, Parallel-Group Non-Inferiority Trial (RE-LY Study).Boehringer lngelheim Pharmaceuticals, Inc.

TREXIMET -Phase IIIb study to evaluate the efficacy and safety of a range of doses of a combinationproduct containing Sumatriptan and Naproxen Sodium for the acute treatment of migraine in adolescentmigrainers ages 12 through 17. GSK Adolescent Migraine Study.

A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety andTolerance of Regadenoson in Subjects with Renal Impairment.

A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety andTolerance of Regadenoson in Subjects with Asthma or Chronic Obstructive Pulmonary Disease(COPD).